Biocon Limited board approves Q4 results, dividend, auditor change and BBL share swap
Biocon · Pharmaceuticals & Biotechnology
Key highlights
- Standalone net profit for the quarter ended March 31, 2026 was Rs. 510 million against Rs. 212 million for the 3 months ended 31.03.2025.
- Board approved acquisition of up to 1,15,36,956 BBL shares for Rs. 330.73 Crores via preferential issue of up to 87,92,317 Biocon shares at Rs. 376.16, subject to shareholder approval.
- Board recommended S. R. Batliboi & Associates LLP as statutory auditors for five years from the 48th AGM on August 6, 2026, replacing B S R & Co. LLP, subject to shareholder approval.
Why it's rated major development: the year-on-year change is 141% (50% or more)
Figures checked against the filing by a second AI read, which corrected the first summary. About the business, not the share price.
Original filing
Outcome Of Board Meeting_Completion Of Tenure Of Statutory Auditors
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Aerospace & Defense
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Biocon
- Order winNotableBiocon secures 10-year Pertuzumab supply contract in Brazil under PDP program
- Fundraise / allotmentNotableBiocon: board okays share swap for ~2% of BBL, Q4 results, Re. 0.50 dividend
- Dividend / buyback / bonusMajor developmentBiocon board approves share swap to acquire remaining BBL stake via preferential issue
- Dividend / buyback / bonusMajor development· Adverse for the businessBiocon reports Q4FY26, FY26 consolidated results; profit before exceptionals down YoY
- Acquisition / mergerNotableBiocon Limited announces acquisition of Biocon Biologics shares via preferential issue
Other acquisition / merger filings this fortnight
- IndiGrid Infrastructure Trust Q2 FY27 Earnings Conference Call Transcript Released
- Cubical Financial Services Ltd announces promoter reclassification post open offer
- Novus Loyalty Limited approves acquisition of AutoPe Payment Solutions via share swap
- Shish Industries Limited files Composite Scheme of Amalgamation proposal
- Jubilant Ingrevia Limited updates on acquisition of 40% stake in Zettaone Technologies
- NHC Foods approves quarter results, 99.98% Sachmaas Foods investment, two appointments
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.